Sun exec: Generic firms will face same tough times as innovators

High-flying Indian generics-maker Sun Pharmaceutical says it expects copycat companies to find themselves in the same uncomfortable position as cliff-hanging drug innovators are today beginning in 2015. Prepare for a struggle as fewer new treatments hit the market with their patent clocks ticking, says Sun chairman and managing director Dilip Shanghvi. His guidance: Copy what innovator drug companies do, not just what they make. Story

Suggested Articles

Transporting pharmaceutical products at <-60C for more than 96 hours has seemed an insurmountable challenge. TOWER’s solution has solved the problem.

Roche will spend $500 million for a new global manufacturing logistics hub in Canada that will eventually employ 500 workers in Ontario.

Fledgling Indiana CDMO Incog BioPharma Services is shelling out $60 million to get its first manufacturing facility off the ground.